Novartis Q1 Preview: Profits Still Under Pressure From Lockdown
Entresto Sales Should Be Strong But Cosentyx May Struggle
Executive Summary
The company will review a challenging quarter next week when its financials will reveal that certain parts of the business are still feeling the effects of the COVID-19 pandemic, its eye drugs in particular.